Improving Your Survival – Find the Right Hospital

Today’s New York Times (8/23/16) had an article written by Austin Frakt, which should be of interest to all of us with prostate cancer. The article, “Why It’s Crucial to Choose the Right Hospital appeared on page A3. The entire article is best described by the first sentence, “There’s an exceeding simple way to get [...]

Radioligand Therapy With 177Lu-PSMA-617 – A Novel Therapeutic Possibility on the Horizon in Men With Metastatic Castration Resistant Prostate Cancer.

We are seeing more and more novel therapies being developed to treat castrate resistant metastatic prostate cancer (mCRPC). One such therapy involves theranostic (individualized therapies for various diseases, and to combine diagnostic and therapeutic capabilities into a single agent) concepts using radiolabeled ligands of the prostate-specific membrane antigen (PSMA). In a recent study, designed to [...]

Xtandi Vs Zytiga

The phase III trials for both Xtandi and Zytiga were similar. Both trials investigated men who progressed or died against placebo. Only 14% of men taking Xtandi during the trial progressed or died compared to 40% of the men in the placebo group. In the phase III trial of Zytiga 28% of the men [...]

For Men with Prostate Cancer Does Being Married or Partnered Extend Your Life, A Myth Shattered

I just returned, along with Malecare’s Executive Director Darryl Mitteldorf and Dr. Wendy Lebowitz, from the ASCO Genitourinary Cancers Symposium in San Francisco. The three of us often attend this meeting, but this one had a new and very special item, a research poster (abstract no. 253) that was presented by Malecare and Mitteldorf. The [...]

Anticoagulants May Increase Survival in Men with Advanced Prostate Cancer Taking Chemotherapy*

Over the past two to three years there have been some small studies that have indicated that the use of concomitant anticoagulants along with docetaxel (chemotherapy) may improve overall survival The most recent examination of this issue was performed by a team led by Emmanuel S. Antonarakis, MD, of Johns Hopkins University in Baltimore.  They [...]

A Statistical Nightmare – Comparing the Efficacy of Zytiga & Xtandi In the Pre-Chemo Setting

Based on the assumption that Enzalutamide (Xtandi) is approved for use in men with castrate resistant metastatic prostate cancer (advanced prostate cancer or mCRPC) who have not had prior chemotherapy, pretty much a foregone conclusion based on the extraordinary phase III Prevail Trial results, including a statistically significant survival advantage of 2.2 months with a [...]

Survival Advantage of Abiraterone Acetate (Zytiga) in Men with Castrate Resistant Metastatic Advanced Prostate Cancer

We all know that abiraterone acetate (Zytiga) plus prednisone provides a survival advantage for men with castrate resistant advanced prostate cancer (mCRPC) who have had prior treatment with a taxane based chemotherapy. New information has shown that abiraterone acetate offers a somewhat longer overall survival benefit than the data originally presented when the trial halted [...]

A Systematic Review – Does Local Treatment of the Prostate in Advanced and/or Lymph Node Metastatic Disease Improve Efficacy of Androgen-Deprivation Therapy?

One of the largest and most controversial issues for the treatment of advanced prostate cancer is the value of androgen-deprivation therapy (ADT). Most doctors use ADT as their pivotal initial treatment in the management of locally advanced and metastatic prostate cancer (PCa). But, the grand question is does it extend survival? […]

Impact of Androgen Blockade on Overall Survival – Is There Any and When Should We Start?

For years there remains this terrible hidden question, does an androgen blockade (ADT) provide any survival advantage to men with early advanced prostate cancer? We do know that ADT will have a significant negative impact on ones life, this is guaranteed. We do know that if we go on a blockade our life will change. [...]

Go to Top